Ergomed plc Result of AGM (3958I)

TIDMERGO

RNS Number : 3958I

Ergomed plc

16 June 2017

PRESS RELEASE

FOR IMMEDIATE RELEASE

Results of 2017 Annual General Meeting

London, UK -16 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.

Resolutions 1 to 5 were passed on a show of hands.

Details of proxy results were as follows:

 
 Resolution   Votes for   Votes against   Abstentions 
  number 
-----------  ----------  --------------  ------------ 
 1            7,173,627   152,834         Nil 
-----------  ----------  --------------  ------------ 
 2            7,325,794   Nil             667 
-----------  ----------  --------------  ------------ 
 3            7,325,794   Nil             667 
-----------  ----------  --------------  ------------ 
 4            7,325,794   Nil             667 
-----------  ----------  --------------  ------------ 
 5            7,315,839   Nil             10,622 
-----------  ----------  --------------  ------------ 
 

Details of voting results for resolutions 6 and 7 (including proxies) were as follows:

 
 Resolution   Votes for    Votes against   Abstentions 
  number 
-----------  -----------  --------------  ------------ 
 6            24,118,915   4,235,625       13,622 
-----------  -----------  --------------  ------------ 
 7            24,118,915   4,235,625       13,622 
-----------  -----------  --------------  ------------ 
 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

ENDS

Enquiries:

 
 Ergomed plc                                             Tel: +44 (0) 
                                                          1483 503205 
 Miroslav Reljanovic (Chief Executive 
  Officer) 
 Stephen Stamp (Chief Financial 
  Officer) 
 
 Numis Securities Limited                                Tel: +44 (0) 
                                                         20 7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                              Tel: +44 (0) 
                                                         20 7496 3000 
 Alex Price (Joint Broker) 
 
 Consilium Strategic Communications                      Tel: +44 (0) 
  - for UK enquiries                                     20 3709 5700 
 Chris Gardner / Mary-Jane                [e-mail] 
  Elliott / Ivar Milligan 
 
 MC-Services - for Continental                           Tel: +49 211 
  European enquiries                                        5292 5222 
 Anne Hennecke 
 
 

About Ergomed

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed acquired a pipeline of proprietary development products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLLFSRRFIRLID

(END) Dow Jones Newswires

June 16, 2017 12:44 ET (16:44 GMT)